Case reportParadoxical response to intravenous immunoglobulin in a case of Parvovirus B19-associated chronic fatigue syndrome
Section snippets
Why this case is important?
The chronic fatigue syndrome (CFS) remains a challenging clinical entity with several expressions overlapping with infectious and autoimmune disorders. According to several pathogenetic hypotheses, in patients with susceptible genetic background, a persisting antigenic/infectious stimulation may trigger a chronic immune activation and upregulation of pro-inflammatory cytokines leading to CFS [1]. Evidence shows that chronic Parvovirus B19 (B19V) infection can be involved in the pathogenesis of
Case description
A 42-year old Italian man was referred (May 2012) to the Infectious Diseases Unit at the S.Orsola-Malpighi University Hospital (Bologna, Italy) with a previous diagnosis of CFS associated with B19V infection. His past medical history included a pericarditis of possible viral origin (18 years before), Gilbert syndrome, and allergic rhinitis-conjunctivitis.
At disease onset, five years earlier, the patient exhibited high-titre anti-B19V serum IgM that progressively declined over 18 months,
Other similar and contrasting cases in the literature
CFS is a composite disorder with variable presentation and clinical course, where ethiopathogenetic pathways may depend on the patient-specific genetic background, different underlying immune response, and a broad spectrum of possible triggering agents. A relevant portion of CFS cases do recognize a directly- or indirectly-mediated infectious disease origin [1]. In these cases, the appropriate treatment of an active infection may significantly contribute to the outcome of CFS. To the best of
Discussion
In our case, repeated high-dose IVIG treatment failed in producing a successful clinical outcome. On the contrary, our patient complained of a transient re-appearance of the most severe signs-symptoms already experienced at disease onset, and symptom exacerbations were accompanied by increased viraemia. Evaluation of immunological responses upon IVIG administration showed no major changes, except for increased levels of B-cell activation. Further, in vitro investigation demonstrated that the
Funding
This work was supported by the University of Bologna (RFO 2010–2012).
Competing interest
None declared.
Ethical approval
Not applicable.
Acknowledgments
We gratefully acknowledge Dr. Daniela Barbieri, PhD, from the Department of Diagnostic, Experimental and Specialty Medicine of the University of Bologna, for valuable suggestions and discussion of data.
References (14)
- et al.
Chronic fatigue syndrome, the immune system and viral infection
Brain Behav Immun
(2012) - et al.
No apparent difference in the prevalence of parvovirus B19 infection between chronic fatigue syndrome patients and healthy controls in Japan
J Clin Virol
(2009) - et al.
Immunological aspects of chronic fatigue syndrome
Autoimmun Rev
(2009) - et al.
Development of an improved method of detection of infectious parvovirus B19
J Clin Virol
(2006) - et al.
Human parvovirus B19 infection of monocytic cell line U937 and antibody-dependent enhancement
Virology
(2006) - et al.
Chronic parvovirus B19 infection resulting in chronic fatigue syndrome: case history and review
Clin Infect Dis
(1997) - et al.
Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome
Clin Infect Dis
(2003)